Provider review
Live Vital Review: 156 Studies on One Page, None on the Product Pages
Live Vital has built the most serious evidence apparatus of any peptide seller reviewed here: 156 study summaries, each keyed to a PubMed ID and reviewed by a named physician. Not one of its fourteen product pages links to it. BPC-157 is sold on "promotes angiogenesis" with no citation, GHK-Cu on "supports collagen and elastin production" with none. The two never meet.
Live Vital is the closest thing we've reviewed to a company that takes evidence seriously, and it has arranged its site so that the evidence never reaches the reader. A 156-study library keyed to PubMed sits one click away from fourteen product pages that link to it zero times. Its GLP-1 claims are careful and correctly attributed; its peptide claims are mechanism recast as benefit, uncited, on products whose human registry records are phase 1 or still recruiting. If you are buying semaglutide or tirzepatide here, the claims are sound and the real price is 30% above the one advertised. If you are buying a peptide, you are being asked to accept three things on trust that the company has chosen not to publish: which pharmacy compounded it, whether that lot was tested, and what evidence supports the sentence that sold it — while the consent form you sign moves responsibility for the first two onto a pharmacy it will not name.
Worth trusting if
- You want the term in writing before you pay, because every protocol page prints the weeks and the total beside the monthly figure.
- You would rather talk to a person first, because the 15-minute consult with Dr. Taylor is a phone call, free, and explicitly not a video visit.
- You are comparing sellers on who actually prescribes, because Live Vital names the one physician who reviews every intake.
Be skeptical if
- You are budgeting by the month, because a 10-week protocol divided by three understates what you pay by about 30%.
- You want to reach support before you have an account, because no phone number and no email address are published anywhere on the site.
- You are buying BPC-157 or TB-500 for tissue repair, because the human registry record for each sits at phase 1 and the product pages cite nothing.
Compounded only
Phase 3 trials
Not named
None found
Disclosure: Some links on this site are affiliate or referral links. If you start a treatment or buy a product through them, we may earn a commission at no additional cost to you. Read our full disclosure.
Opens www.livevital.io. A link is not a recommendation to take anything.
Provenance
What Live Vital actually dispenses
Regulatory category is the axis consumers are most reliably misled about, so it comes first. Every product below is sorted by what it legally is, not by what it costs.
Prepared by a state-licensed pharmacy against a prescription for a named patient. Compounded preparations are not FDA-approved and are not reviewed by FDA for safety, effectiveness or quality.
- BPC-157 (10-week protocol) — $297 per 10-week protocol, advertised as "$99/mo". Ten weeks is 2.31 months, so the real figure is $128.70 a month.
- TB-500 (10-week protocol) — $297 per 10-week protocol, advertised as "$99/mo"; $128.70 a month in fact.
- CJC-1295/Ipamorelin (10-week protocol) — $349 per 10-week protocol, advertised as "$116/mo"; $151.23 a month in fact.
- MOTS-c (10-week protocol) — $449 per 10-week protocol, advertised as "$149/mo"; $194.57 a month in fact.
- NAD+ injection (10-week protocol) — $249 per 10-week protocol, advertised as "$83/mo"; $107.90 a month in fact.
- Semaglutide (10-week protocol) — $299 per 10-week protocol, advertised as "$99/mo"; $129.57 a month in fact.
- Tirzepatide (10-week protocol) — $549 per 10-week protocol, advertised as "$183/mo"; $237.90 a month in fact.
Evidence
Has the molecule been tested for what it is sold for?
One row per product, graded on how far the published human evidence goes for the MOLECULE inside it, for the use it is sold for — not for the molecule in general, and never a claim about this seller. Nobody trials a compounded preparation; what a trial can tell you is whether the molecule has been tested for the thing it is being advertised to do. A molecule with phase 3 evidence for one outcome has none for another, and that distinction is where peptide marketing lives.
6
Molecules with human evidence
For the use they are sold for, out of 7 products reviewed here. The evidence belongs to the molecule, not to Live Vital.
6
Registry records cited
Each read live from ClinicalTrials.gov, never from memory. None of them tested this company's product.
The comparison
What they claim, against what the trials show
Each claim below is quoted verbatim from Live Vital’s own page, with the page it came from. Grading a paraphrase would prove nothing. Every row is the verdict at a glance — tap it to open the quote, the trial registry entries, and the full note behind that verdict.
BPC-157 (10-week protocol)BPC-157 · Compounded (503A)No trial supports this claim
“A 15-amino-acid peptide that concentrates its repair effects right at the site of injury. Promotes angiogenesis to support blood flow to injured tissue. Supports gut lining repair. Accelerates local healing through growth factor activity and collagen production.”
Read on the Live Vital site, August 2026
Phase 1 only
What the trials show for BPC-157
- NCT02637284 — Phase 1, unknown status, n=42. The registry record for BPC-157 in humans sits at phase 1 — the stage that establishes tolerability, not effect.
Three mechanistic assertions — angiogenesis, gut-lining repair, collagen production through growth-factor activity — stated as things the product does, with no citation on the page. The human registry record for BPC-157 is phase 1, which asks whether a dose is tolerated and cannot answer whether tissue heals faster. The animal literature Live Vital is describing is real and it is animal literature; nothing on the page marks that boundary. Live Vital's own research library holds summaries that would have qualified this, and the product page links to none of them.1
TB-500 (10-week protocol)TB-500 (thymosin beta-4 fragment) · Compounded (503A)Claim reaches past the trials
“A synthetic version of thymosin beta-4 that supports repair systemically, not just at one site. Upregulates actin to support systemic cell migration and tissue repair. May improve flexibility and range of motion.”
Read on the Live Vital site, August 2026
Phase 1 only
- NCT07487363 — Phase 1/Phase 2, recruiting, n=80. TB-500 itself. The larger thymosin beta-4 program is a different molecule at a different stage.
The actin mechanism is a real property of thymosin beta-4 and is fairly stated. The overstatement is the leap from that to "may improve flexibility and range of motion" — an outcome claim about how a person moves, resting on a phase 1 record for the fragment and on a separate thymosin beta-4 program that is not the product being sold. "Supports repair systemically" is a mechanism recast as a benefit.2
CJC-1295/Ipamorelin (10-week protocol)CJC-1295 and ipamorelin · Compounded (503A)No trial supports this claim
“Most patients notice they're sleeping differently within the first two weeks. Ipamorelin's selectivity means minimal effect on cortisol, prolactin, or appetite.”
Read on the Live Vital site, August 2026
Phase 2 only
- NCT00267527 — Phase 2, terminated, n=120. Terminated, not completed — and it studied CJC-1295 in HIV patients with visceral obesity, i.e. hormone release in a specific clinical population, not sleep architecture in healthy adults.
"Most patients notice they're sleeping differently within the first two weeks" is a claim about incidence and timing — the shape of a trial result — offered with no trial. The selectivity statement about cortisol, prolactin and appetite is the better-supported half and is genuinely a property of ipamorelin, but the sleep claim is the one leading the page, and nothing on the site measures it.3
MOTS-c (10-week protocol)MOTS-c · Compounded (503A)Claim reaches past the trials
“Make your metabolism work harder, even without changing your diet. Activates the AMPK pathway, the same cellular energy sensor triggered by exercise.”
Read on the Live Vital site, August 2026
Phase 2 only
- NCT07505745 MOTS-MET — Phase 2, recruiting, n=120. Recruiting, not reporting. No completed human efficacy result exists to support a metabolic-outcome claim.
The AMPK statement is accurate mechanism and is the honest part of the page. "Make your metabolism work harder, even without changing your diet" is an outcome promise built on top of it, and the only registry record is a phase 2 trial that is still recruiting. A mechanism shared with exercise is not a result comparable to exercise, and the headline invites exactly that reading.4
NAD+ injection (10-week protocol)NAD+ · Compounded (503A)No trial supports this claim
“Feel like yourself again. NAD+ declines with age. This restores it. Supports the cellular processes involved in DNA repair.”
Read on the Live Vital site, August 2026
No trial for this use
As of 10 August 2026, a ClinicalTrials.gov v2 intervention search for injected NAD+ in humans returns no completed randomized trial supporting a restoration-of-function claim, and a PubMed search for "nicotinamide adenine dinucleotide" combined with injection or subcutaneous, filtered to the randomized-controlled-trial publication type, returns zero records. The substantial human literature concerns ORAL precursors — nicotinamide riboside and nicotinamide mononucleotide — which are different molecules by a different route, and whose results do not transfer to an injection any more than oral iron transfers to an infusion.
"NAD+ declines with age. This restores it." is two sentences doing very different work. The decline is well documented. That injecting NAD+ restores it — and that restoring it makes a person "feel like yourself again" — is the part with no completed human trial behind it. Worth noting for contrast: a competitor selling the same molecule states on its own page that "research on supplemental NAD+ is still developing". Live Vital's page carries no such qualification.
Semaglutide (10-week protocol)Semaglutide · Compounded (503A)Claim matches the trials
“In the STEP-1 trial, adults without diabetes taking semaglutide for weight management lost an average of roughly 15% of their body weight over 68 weeks.”
Read on the Live Vital site, August 2026
Phase 3 trials
What the trials show for Semaglutide
- NCT03548935 STEP 1 — Phase 3, completed, n=1,961. Tested the approved 2.4 mg product. No compounded semaglutide from any seller has been through a registered trial.
Accurately stated. The trial is named, the population is correctly described as adults without diabetes, the figure and the 68-week duration are right. The single reservation is the one that applies to every compounded seller: STEP 1 tested the finished approved product, not a compounded preparation, and the page does not mark that difference. It is nonetheless among the more careful GLP-1 claims we've reviewed — it names the trial rather than saying "clinical studies show".5
Tirzepatide (10-week protocol)Tirzepatide · Compounded (503A)Claim matches the trials
“In the SURMOUNT-1 trial, participants without diabetes taking the highest dose lost an average of roughly 20% of their body weight over 72 weeks.”
Read on the Live Vital site, August 2026
Phase 3 trials
What the trials show for Tirzepatide
- NCT04184622 SURMOUNT-1 — Phase 3, completed, n=2,539. Tested the approved product at the highest tolerated dose over 72 weeks.
Correct on every particular a reader could check: trial named, population, dose qualifier, magnitude and duration. Same standing caveat as semaglutide — the trial tested the approved product, not a compounded one, and the page does not say so.6
Dispensing chain
Who actually fills your prescription
Read the full account
No pharmacy is named anywhere on livevital.io — checked across all 26 pages fetched. The formulation is consistent and consistently anonymous: "Medications compounded at 503A-licensed pharmacies" on the partner-treatments footer; "the prescription must go to a 503A pharmacy, where the peptide is compounded for each specific patient and undergoes testing" in the FAQ; "All 503A pharmacies that Live Vital partners with should provide you with instructions for proper sterile subcutaneous injection" — plural, unnamed, throughout. The regulatory category IS stated, which is more than most manage: 503A, repeatedly and unambiguously. What is withheld is which one. That matters more here than usual, because Live Vital's own peptide-therapy consent asks the patient to acknowledge that it "is not responsible for any manufacturing issues related to peptides prepared by compounding pharmacies and that the sole responsibility for sterility, potency, and safety lie with these pharmacies." Responsibility is assigned, in writing, to a party the reader is never allowed to identify.
Read on the Live Vital site, August 2026.
Quality
Third-party testing, and what is published
Describes a testing regime
Nothing published on the pages searched
Certificate of analysis readable
No lot report a buyer can open
Read the full testing account
Nothing is published. No certificate of analysis, no batch record, no potency or sterility result, no named laboratory, no lot lookup — across the whole site. The testing language is entirely second-hand and unverifiable: the peptide "undergoes testing" at the pharmacy, pharmacies are "required to comply with applicable USP standards", and pharmacies "can extend this timeframe based on their own rigorous safety testing." Every one of those attributes the testing to the pharmacy, and the pharmacy is never named — so a reader has neither the document nor anyone to ask for it. Two shelf-life statements in the FAQ go further than any document on the site supports: that medication "and its potency are good for 6 months after opening", and that "most peptides are stable and safe if refrigerated for over 180 days" — the latter set explicitly against the 90-day beyond-use date the compounding pharmacy assigns. Those are stability claims contradicting the dispensing pharmacy's own limit, made by the party that has disclaimed responsibility for potency.
Read on the Live Vital site, August 2026.
Licensing
Licensed to dispense, and where
Coverage
All 50 states by its marketing, Utah plus 'where permitted' by its terms
Read the full licensing claim
Live Vital's site-wide footer says "Serving all 50 states" and its FAQ says it "is licensed to provide care in all 50 states through our telehealth platform." Its intake does offer all fifty plus the District of Columbia, and a Texas selection passed the eligibility gate. Its Terms §4 say something materially weaker: services are "available to residents of Utah and patients nationwide where telehealth is permitted." The signup flow adds a third position — "Certain medications can only be shipped to select states" — and no exclusion list is published anywhere, so this review lists none: naming exclusions would mean inventing them, not because none exist. No state requires a video visit; the intake is self-serve everywhere and a 15-minute phone consultation is optional and free.
Read on the Live Vital site, August 2026.
Regulatory
The FDA warning letter
Checked, and none found
We did this ourselves
What happens when you sign up with Live Vital
We went through Live Vital’s signup ourselves in August 2026 to find out what you actually meet before you pay — the steps, when a price appears, and what it asks for. We used placeholder answers, and we stopped before paying, so nothing here is a prescription or a medical outcome. It is what the screens showed.
- Pick a protocol on a treatment page, where the monthly figure, the protocol length and the total are printed together.
- Press Start intake, which hands you to the care portal at care.livevital.io.
- Say whether you already know which therapy you want.
- Choose a goal, then choose the therapy itself.
- Choose your state from a list that offers all fifty plus the District of Columbia.
- Give your first and last name, your date of birth, and your sex.
- Give a phone number or an email address, and enter the verification code sent to it before anything else loads.
- Every protocol page prints its price, its length and its total on one line, which almost nothing else in this category does: BPC-157 reads "$99/mo, 10-week protocol ($297 total)".
- Eleven of the thirteen priced protocols run 10 weeks, and every one divides its total by three to reach the monthly figure. Ten weeks is 2.31 months, so the advertised rate understates what you actually pay by about 30%. Only NAD+ and glutathione are billed on a real three-month term.
- The FAQ says treatment runs "$99 to $299 per month". The top of that range is not a monthly rate at all — it is the 10-week total for semaglutide, and no protocol page lists a monthly figure anywhere near it.
- Semaglutide and tirzepatide have full priced pages, but neither is listed on the treatments page or in the footer, so you reach them only from a search result or a direct link.
- The intake stops at a code sent to your phone or email. No price, dose or pharmacy appears between the treatment page and that gate, so everything past it is private.
- No support phone number or email address is published anywhere. Support runs through a portal that needs the account the code creates, and the only public contact is a free 15-minute phone consult booked through a scheduler.
Assessment
What holds up, and what does not
- It built a real evidence library — 156 study summaries keyed to PubMed IDs, written in plain language, each marked as reviewed by a named physician. Nothing else we've reviewed comes close.
- Its two GLP-1 claims are among the most careful we have graded: both name the actual trial, state the population correctly, and get the magnitude and duration right.
- It states its regulatory category plainly and repeatedly — 503A, patient-specific compounding — where most sellers say only "licensed pharmacy".
Show 5 more
- The prescribing clinician is named: Dr. Patrick Taylor, MD, described as reviewing every intake personally.
- Its counter-positioning against gray-market peptides is specific rather than vague, naming what it is not: "'research use only' peptides come with no physician, no dosing guidance, and no quality accountability, and they are not intended for human use."
- The protocol total is printed beside every monthly figure, so the amount actually charged is always on the page.
- No FDA warning letter for Live Vital.
- No intro pricing anywhere. Every figure is a standing protocol price, so nothing expires into something higher.
- The research library is orphaned. Zero of the fourteen product pages link to /research, so every claim is made on a page with no citation while every citation sits on a page with no product.
- No product page cites a trial identifier. Three name trials in prose with no NCT number and no link; the other eleven cite nothing at all.
- No pharmacy is named — while the peptide consent assigns "sole responsibility for sterility, potency, and safety" to those unnamed pharmacies.
Show 5 more
- No certificate of analysis, batch record or third-party test result is published anywhere, for any product.
- Two FAQ shelf-life claims exceed the dispensing pharmacy's own beyond-use date: potency "good for 6 months after opening", and peptides "stable and safe if refrigerated for over 180 days" against a stated 90-day BUD.
- Every advertised price understates the real monthly cost by about 30%, because a 10-week protocol is divided by three months rather than 2.31.
- "Serving all 50 states" sits opposite Terms §4, which limits services to "residents of Utah and patients nationwide where telehealth is permitted", and no exclusion list is published despite a warning during signup that restrictions exist.
- The most-claimed products are the least-evidenced: BPC-157, GHK-Cu and the three blends carry mechanistic assertions with no citation and, for the blends, no registry record at all.
Verdict
The bottom line
The research library is real and it is worth reading — just do not mistake it for the evidence behind what you are buying, because no product page links to it and the claims on those pages carry no citation at all. Ask Live Vital which of its 156 studies supports the specific sentence on the product page you are looking at.
Opens www.livevital.io. A link is not a recommendation to take anything.
A library nobody is sent to
Live Vital publishes 156 study summaries at `/research`. Each is keyed to a PubMed ID, written in plain language, tagged by compound, and marked "reviewed by Dr. Patrick Taylor, MD. Educational only, not medical advice." It is a genuine piece of work, and it is more than any other seller in this category has built.
Now open a product page. BPC-157 is sold on "promotes angiogenesis to support blood flow to injured tissue" and "accelerates local healing through growth factor activity and collagen production." GHK-Cu on "supports collagen and elastin production." MOTS-c on "activates the AMPK pathway, the same cellular energy sensor triggered by exercise."
None of those pages links to the library. Not one. We checked all fourteen product pages for a link to `/research` and found zero.
So the site contains both halves of a properly evidenced claim and never joins them. The reader who lands on the BPC-157 page — which is the reader deciding whether to spend $297 — sees three mechanistic assertions and no citation. The reader who lands on the research library sees citations and nothing to buy. Live Vital has done the hard part and skipped the easy one.
Full analysis — 5 more sectionsWhat the registry actually says about these molecules · Where the claims are good · The sentence you are asked to sign · Two shelf-life claims that outrun the pharmacy · What this means if you are buying
What the registry actually says about these molecules
The claims are not fabrications. They describe real mechanisms drawn from real literature. The question this site asks is narrower: does the evidence reach as far as the sentence does?
For BPC-157, the human registry record sits at phase 1. 1 Phase 1 asks whether a dose is tolerated. It cannot answer whether tissue heals faster, whether blood vessels form, or whether a gut lining repairs — which are the three things the product page asserts. The animal literature behind those assertions is substantial and it is animal literature; nothing on the page marks that line.
TB-500's own registry record is also phase 1, and recruiting. 2 The broader thymosin beta-4 program is further along, but thymosin beta-4 is a different molecule from the fragment being sold, and the page moves between them without saying so.
MOTS-c has a phase 2 trial that is recruiting, not reporting. 4 "Activates the AMPK pathway" is accurate. "Make your metabolism work harder, even without changing your diet" is a promise about outcomes, and the trial that might one day support it has not finished enrolling.
The CJC-1295 and ipamorelin literature is phase 2 and concerns growth hormone release. 3 The page leads with "most patients notice they're sleeping differently within the first two weeks" — a claim about incidence and timing, which is the shape of a trial result, offered without one.
Where the claims are good
It is worth being precise about what Live Vital gets right, because it is unusual.
Its semaglutide page says: "In the STEP-1 trial, adults without diabetes taking semaglutide for weight management lost an average of roughly 15% of their body weight over 68 weeks." Every element of that is correct. STEP 1 randomized 1,961 adults to once-weekly semaglutide 2.4 mg or placebo for 68 weeks. 5 The population is correctly described, the figure is right, the duration is right, and the trial is named rather than gestured at with "clinical studies show".
Its tirzepatide page does the same with SURMOUNT-1 — 2,539 participants, 72 weeks, roughly 20% at the highest dose. 6 Also correct.
That is a higher standard than most of this category reaches, and it makes the contrast with the peptide pages sharper rather than softer. The company clearly knows how to attach a claim to a trial. It does it for the two molecules that have trials, and not for the ones that do not.
The sentence you are asked to sign
Live Vital's peptide-therapy consent contains this, verbatim:
"I acknowledge that Live Vital is not responsible for any manufacturing issues related to peptides prepared by compounding pharmacies and that the sole responsibility for sterility, potency, and safety lie with these pharmacies."
That is a reasonable division of responsibility. A telehealth platform does not compound anything, and saying so is honest.
It only works, though, if the reader can identify the pharmacy. And Live Vital never names one. Across 26 pages it says "503A-licensed pharmacies", "all 503A pharmacies that Live Vital partners with", "a licensed US compounding pharmacy" — always plural, always anonymous.
So the consent moves responsibility for sterility and potency onto a party, and the site withholds that party's identity. If a lot were wrong, the document you signed tells you whose problem it is and the website tells you nothing about how to reach them.
No certificate of analysis is published either — no batch record, no potency result, no sterility result, no named laboratory, for any product. The FAQ says the peptide "undergoes testing" at the pharmacy. That is a claim about the unnamed party, made by the party that has disclaimed responsibility.
Two shelf-life claims that outrun the pharmacy
The FAQ states that "the pharmacy and our doctors say that the medication and its potency are good for 6 months after opening. Many patients use it longer with no issues."
And, more directly: "BUDs are set 90 days from the last day of compounding… although the reality is that most peptides are stable and safe if refrigerated for over 180 days."
A beyond-use date is the compounding pharmacy's own limit on how long its preparation can be relied upon. The second sentence acknowledges that limit is 90 days and then tells the reader the real number is double it. That advice comes from the company that has, in its consent form, assigned potency to somebody else.
What this means if you are buying
For semaglutide or tirzepatide, the claims on these pages are accurate and better attributed than most. Check the price arithmetic — a 10-week protocol advertised as "$X/mo" is divided by three months when ten weeks is 2.31, so the real monthly cost is about 30% above the figure shown.
For any of the peptides, the questions to settle before paying are the ones the site does not answer: which 503A pharmacy compounds it, whether that lot was tested and by whom, and what evidence stands behind the sentence that persuaded you. Live Vital has 156 study summaries that speak to the last one. It has simply never put a link to them where you would look.
Compare
Others selling what Live Vital sells
Companies we have also reviewed that dispense at least one of the same compounds, ordered by how much of what they say about their products matches the trials behind them. Nothing here is a recommendation, and none of these links earns us anything.
Method
How we checked this
Non-product facts last checked August 2026. Read the editorial policy for the rules this page is held to.
Read our methodology
Claims read first-party
Every quoted claim was read off Live Vital's own pages, first-hand, on the date stamped against it — never from a summary, an aggregator, or an earlier version of this review.
Trials read from the registry
Phase, status and enrollment come from ClinicalTrials.gov; identifiers and journals from PubMed's own records. Nothing here is cited from memory.
Absence claims bounded
Where we report that no trial exists, the page says what was searched, where, and when — never an unbounded claim that nobody has tested something.
Letters matched on full name
FDA letters are matched on the complete company name. A substring match would attach one firm's regulatory history to another with a similar name.
Sources
References
Show all 6 sources
- US National Library of Medicine (2026). BPC-157 — registry record, phase 1, NCT02637284. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT02637284
- US National Library of Medicine (2026). TB-500 (thymosin beta-4 fragment) — registry record, phase 1, NCT07487363. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07487363
- US National Library of Medicine (2026). Growth hormone secretagogue — registry record, phase 2, NCT00267527. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT00267527
- US National Library of Medicine (2026). MOTS-MET — MOTS-c registry record, phase 2, recruiting, NCT07505745. Read 2026-08-10.. ClinicalTrials.gov. https://clinicaltrials.gov/study/NCT07505745
- Wilding JPH, Batterham RL, Calanna S, et al. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine 384(11):989-1002. https://pubmed.ncbi.nlm.nih.gov/33567185/
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine 387(3):205-216. https://pubmed.ncbi.nlm.nih.gov/35658024/
Medical disclaimer: This content is for general educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a licensed healthcare professional before starting, stopping, or changing any treatment.